These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 32719125)

  • 1. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
    Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
    Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
    Ward TA; McHugh PJ; Durant ST
    PLoS One; 2017; 12(6):e0179278. PubMed ID: 28628639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression.
    He L; Zhang Y; Sun H; Jiang F; Yang H; Wu H; Zhou T; Hu S; Kathera CS; Wang X; Chen H; Li H; Shen B; Zhu Y; Guo Z
    EBioMedicine; 2016 Dec; 14():32-43. PubMed ID: 27852524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Setting molecular traps in yeast for identification of anticancer drug targets.
    Brown GW; Andrews B
    Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33853860
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
    Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
    He L; Luo L; Zhu H; Yang H; Zhang Y; Wu H; Sun H; Jiang F; Kathera CS; Liu L; Zhuang Z; Chen H; Pan F; Hu Z; Zhang J; Guo Z
    Mol Oncol; 2017 Jun; 11(6):640-654. PubMed ID: 28371273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of human FEN1 in Saccharomyces cerevisiae and its role in genome stability.
    Greene AL; Snipe JR; Gordenin DA; Resnick MA
    Hum Mol Genet; 1999 Nov; 8(12):2263-73. PubMed ID: 10545607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
    Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; Banáth J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
    Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells.
    Zhang J; Chen M; Pang Y; Cheng M; Huang B; Xu S; Liu M; Lian H; Zhong C
    J Exp Clin Cancer Res; 2022 Apr; 41(1):140. PubMed ID: 35414100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy.
    Yang F; Hu Z; Guo Z
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Succinylation at a key residue of FEN1 is involved in the DNA damage response to maintain genome stability.
    Shi R; Wang Y; Gao Y; Xu X; Mao S; Xiao Y; Song S; Wang L; Tian B; Zhao Y; Hua Y; Xu H
    Am J Physiol Cell Physiol; 2020 Oct; 319(4):C657-C666. PubMed ID: 32783654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.
    Andronikou C; Burdova K; Dibitetto D; Lieftink C; Malzer E; Kuiken HJ; Gogola E; Ray Chaudhuri A; Beijersbergen RL; Hanzlikova H; Jonkers J; Rottenberg S
    EMBO J; 2024 Mar; 43(6):1015-1042. PubMed ID: 38360994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saccharomyces cerevisiae flap endonuclease 1 uses flap equilibration to maintain triplet repeat stability.
    Liu Y; Zhang H; Veeraraghavan J; Bambara RA; Freudenreich CH
    Mol Cell Biol; 2004 May; 24(9):4049-64. PubMed ID: 15082797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
    Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
    J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
    Al-Mugotir M; Lovelace JJ; George J; Bessho M; Pal D; Struble L; Kolar C; Rana S; Natarajan A; Bessho T; Borgstahl GEO
    PLoS One; 2021; 16(3):e0248941. PubMed ID: 33784323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.